Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oleynikov, Valentin
FORPE, NCT04688320: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase	Completed	3	310	RoW	Recombinant nonimmunogenic staphylokinase, Fortelyzin, Alteplase, Actillyze	Supergene, LLC	Massive Pulmonary Embolism	07/23	07/23
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Solovyev, Oleg V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Tavlueva, Evgenia V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oleynikov, Valentin
FORPE, NCT04688320: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase	Completed	3	310	RoW	Recombinant nonimmunogenic staphylokinase, Fortelyzin, Alteplase, Actillyze	Supergene, LLC	Massive Pulmonary Embolism	07/23	07/23
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Solovyev, Oleg V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Tavlueva, Evgenia V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28